Abstract: Carboplatin is a second-generation platinum-based chemotherapeutic agent widely utilized in the treatment of various malignancies, including ovarian, lung, and triple-negative breast cancers. Developed to mitigate the severe systemic toxicities associated with cisplatin, carboplatin functions by forming DNA crosslinks that disrupt replication and transcription, ultimately inducing apoptosis. Despite its clinical success, the development of intrinsic and acquired platinum resistance remains a major obstacle to curative outcomes. Resistance mechanisms are multifaceted, encompassing reduced cellular accumulation, enhanced drug detoxification via glutathione (GSH), augmented DNA repair pathways (such as homologous recombination), and the activation of anti-apoptotic survival signaling. This review synthesizes current literature on carboplatin, detailing its pharmacological activity, molecular mechanisms, and structure-activity relationships. Furthermore, it highlights current clinical limitations and explores future perspectives focused on platinum resistance reversal, including the use of GSH-depleting nanomedicines, mTOR pathway inhibitors, PARP inhibitors, and advanced single-cell proteomic profiling to overcome tumor microenvironment-mediated resistance.
1. Introduction
Chemotherapy remains a cornerstone of anti-tumor treatment, with platinum-based drugs playing a pivotal role since the discovery of cisplatin in the late 1960s [3]. Cisplatin, the first-generation platinum drug approved in 1978, demonstrated significant efficacy but was severely limited by non-specific systemic toxicities, including nephrotoxicity, neurotoxicity, and ototoxicity [3]. To address these adverse effects, carboplatin was developed as a second-generation platinum chemotherapy and received FDA approval in 1986 [3]. Carboplatin exhibits a much higher biosafety profile and significantly reduced systemic toxicity, allowing it to be administered in high-dose regimens for aggressive tumors [3]. Today, it is a standard-of-care agent for numerous cancers, including high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) [2][6]. However, the clinical utility of carboplatin is frequently hindered by the emergence of drug resistance, which occurs in a large percentage of patients during sequential treatments [1][2]. Consequently, understanding the molecular underpinnings of carboplatin resistance and developing strategies for resistance reversal have become critical research imperatives.
2. Pharmacological Activity
Carboplatin exerts potent anti-tumor activity by acting as a DNA-damaging agent. In clinical practice, it is frequently utilized in combination regimens to maximize efficacy. For instance, in early-stage TNBC, the addition of carboplatin to neoadjuvant chemotherapy (often alongside paclitaxel) significantly increases pathological complete response (pCR) rates, exploiting the inherent DNA repair defects (such as BRCAness) common in these tumors [6]. In advanced ovarian cancer, carboplatin combined with paclitaxel has been the front-line standard of care for decades [2]. The pharmacological dosing of carboplatin is uniquely tailored to individual patients using the Calvert formula, which calculates the required dose based on a target area under the curve (AUC) and the patient's glomerular filtration rate (GFR), ensuring optimal systemic exposure while minimizing toxicity [4][5].
3. Molecular Mechanism of Action
The primary cytotoxic mechanism of carboplatin involves its interaction with DNA. Upon entering the tumor cell—partially mediated by copper transporters like CTR1 and organic cation transporters—the drug undergoes activation [1][3]. The relatively low intracellular chloride concentration triggers the replacement of its ligands with water molecules, forming a reactive cationic hydrate [3]. This activated complex binds covalently to DNA, preferentially at the N7 position of guanine, generating mono-adducts as well as intra-strand and inter-strand crosslinks [2][3]. These structural distortions activate the DNA damage response (DDR), halting the cell cycle to allow for repair. If the damage is too severe to be repaired, the cell undergoes apoptosis or mitotic catastrophe [2].
Tumor cells develop resistance to carboplatin through multiple complex mechanisms:
1. Altered Drug Transport: Resistance can arise from decreased drug influx (e.g., downregulation of CTR1) or increased efflux mediated by ATP-binding cassette (ABC) transporters (such as ABCC2/MRP2) and copper exporters (ATP7A/B) [1][2].
2. Detoxification and Sequestration: Intracellular nucleophilic scavengers, particularly glutathione (GSH) and metallothioneins, avidly bind and inactivate carboplatin. Elevated levels of GSH and glutathione S-transferase (GST) enzymes are strongly correlated with platinum resistance [1][3].
3. Enhanced DNA Repair: Upregulation of Nucleotide Excision Repair (NER) proteins (e.g., ERCC1) and Homologous Recombination (HR) pathways allows cells to tolerate and repair platinum-induced DNA lesions. A major mechanism of acquired resistance is the restoration of HR function, often through secondary reversion mutations in BRCA1/2 genes [1][2].
4. Cell Survival Pathways: Resistant cells often exhibit alterations in apoptotic signaling, such as the overexpression of anti-apoptotic BCL-2 family proteins, mutations in TP53, and the hyperactivation of survival pathways including PI3K/AKT/mTOR, TGFβ, and NFκB [1].
4. Structure-Activity Relationship (SAR)
Carboplatin is a Pt(II) complex structurally distinct from cisplatin. While cisplatin utilizes two chloride ions as leaving groups, carboplatin features a bidentate cyclobutane dicarboxylic acid ligand [3]. This structural modification is central to its pharmacological profile. The bidentate ligand is significantly more stable and less prone to aquation (hydration) compared to the chloride ligands of cisplatin [3]. Because of this slower reaction kinetics, carboplatin is less reactive with off-target proteins and nucleophiles in the systemic circulation. This stability directly translates to its improved biosafety profile, drastically reducing the incidence of severe nephrotoxicity, neurotoxicity, and ototoxicity, while maintaining the core DNA-crosslinking capability of the platinum center once activated inside the tumor cell [3].
5. Current Limitations
Despite its advantages over cisplatin, carboplatin therapy faces significant clinical limitations. First, while non-hematological toxicities are reduced, carboplatin is associated with severe dose-limiting myelosuppression, particularly neutropenia and thrombocytopenia [6]. Second, the development of drug resistance remains the primary cause of treatment failure. In HGSOC, for example, while up to 60% of tumors initially respond, 70-80% of patients will eventually acquire platinum resistance, leading to recurrent disease with poor survival outcomes [2]. Finally, the tumor microenvironment (TME) plays a protective role against carboplatin. Factors such as hypoxia (mediated by HIF1A), extracellular matrix remodeling (where collagen and fibronectin activate survival signaling like PI3K/AKT), and immune system-induced chronic inflammation contribute to a highly immunosuppressive and chemoresistant niche [1][2].
6. Future Perspectives
Research into reversing carboplatin resistance is rapidly advancing, focusing on targeted therapies, nanomedicine, and precision oncology:
1. GSH-Depleting Nanomedicines: Because GSH-mediated detoxification is a primary resistance mechanism, novel nanodrugs are being engineered to scavenge intracellular GSH. For example, sulforaphane-cisplatin/carboplatin nanoparticles and carboplatin-lauric acid nanoparticles (CBP-LA NPs) have been shown to deplete GSH levels, thereby preventing the formation of inactive Pt-GSH adducts and restoring platinum sensitivity in resistant tumors [3].
2. Targeting Survival Pathways: The aberrant activation of the PI3K/AKT/mTOR pathway is closely linked to platinum resistance. Clinical trials are currently evaluating dual mTORC1/2 inhibitors, such as sapanisertib, in combination with carboplatin and paclitaxel. Preclinical and early phase I data suggest that mTOR inhibition can restore sensitivity to platinum chemotherapy and enhance cancer cell death [7].
3. PARP Inhibitors and Synthetic Lethality: Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality in tumors with homologous recombination deficiency (HRD). While PARPi have transformed maintenance therapy, functional CRISPR-Cas9 screening is actively identifying overlapping gene dependencies between PARPi and carboplatin to optimize combination strategies and overcome acquired resistance [2][9].
4. Advanced Drug Delivery Systems: The development of platinum nanoclusters (Pt NCs), magnetic nanocarriers (e.g., SPIONs), and mesoporous silica nanoparticles offers the potential to improve tumor-targeted delivery, increase intracellular accumulation, and bypass traditional efflux pump-mediated resistance while further minimizing systemic toxicity [3].
5. Single-Cell Proteomics: Utilizing multiparameter single-cell technologies like Mass Cytometry (CyTOF) and multiplex cellular imaging will allow researchers to map the complex tumor microenvironment. By identifying specific cell phenotypes and spatial arrangements that confer carboplatin resistance, these technologies will guide the development of personalized, multimodal biomarker strategies [2].
